🚀 VC round data is live in beta, check it out!
10x Genomics Valuation Multiples
Discover revenue and EBITDA valuation multiples for 10x Genomics and similar public comparables like Veracyte, Twist Bioscience, BGI Genomics, Genus and more.
10x Genomics Overview
About 10x Genomics
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
Founded
2012
HQ
Employees
1.2K
Website
Financials (LTM)
EV
$2B
10x Genomics Financials
10x Genomics reported last 12-month revenue of $636M and negative EBITDA of ($44M).
In the same LTM period, 10x Genomics generated $438M in gross profit, ($44M) in EBITDA losses, and had net loss of ($60M).
Revenue (LTM)
10x Genomics P&L
In the most recent fiscal year, 10x Genomics reported revenue of $643M and EBITDA of $4M.
10x Genomics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $636M | XXX | $643M | XXX | XXX | XXX |
| Gross Profit | $438M | XXX | $444M | XXX | XXX | XXX |
| Gross Margin | 69% | XXX | 69% | XXX | XXX | XXX |
| EBITDA | ($44M) | XXX | $4M | XXX | XXX | XXX |
| EBITDA Margin | (7%) | XXX | 1% | XXX | XXX | XXX |
| EBIT Margin | (12%) | XXX | (9%) | XXX | XXX | XXX |
| Net Profit | ($60M) | XXX | ($44M) | XXX | XXX | XXX |
| Net Margin | (9%) | XXX | (7%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
10x Genomics Stock Performance
10x Genomics has current market cap of $3B, and enterprise value of $2B.
Market Cap Evolution
10x Genomics' stock price is $22.37.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $3B | 0.0% | XXX | XXX | XXX | $-0.34 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free Trial10x Genomics Valuation Multiples
10x Genomics trades at 3.8x EV/Revenue multiple, and (55.1x) EV/EBITDA.
EV / Revenue (LTM)
10x Genomics Financial Valuation Multiples
As of March 25, 2026, 10x Genomics has market cap of $3B and EV of $2B.
Equity research analysts estimate 10x Genomics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
10x Genomics has a P/E ratio of (47.8x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 3.8x | XXX | 3.8x | XXX | XXX | XXX |
| EV/EBITDA | (55.1x) | XXX | 618.8x | XXX | XXX | XXX |
| EV/EBIT | (32.3x) | XXX | (40.5x) | XXX | XXX | XXX |
| EV/Gross Profit | 5.5x | XXX | 5.4x | XXX | XXX | XXX |
| P/E | (47.8x) | XXX | (65.6x) | XXX | XXX | XXX |
| EV/FCF | (289.6x) | XXX | 18.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified 10x Genomics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
10x Genomics Margins & Growth Rates
10x Genomics' revenue in the last 12 month declined by (2%).
10x Genomics' revenue per employee in the last FY averaged $0.5M.
10x Genomics' rule of 40 is (9%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
10x Genomics' rule of X is (12%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
10x Genomics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (2%) | XXX | (5%) | XXX | XXX | XXX |
| EBITDA Margin | (7%) | XXX | 1% | XXX | XXX | XXX |
| EBITDA Growth | 107% | XXX | (2805%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (9%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (12%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.5M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 36% | XXX | 37% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 86% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
10x Genomics Public Comps
See public comps and valuation multiples for other Life Sciences Tools and Diagnostics & Genomics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Veracyte | XXX | XXX | XXX | XXX | XXX | XXX |
| Twist Bioscience | XXX | XXX | XXX | XXX | XXX | XXX |
| BGI Genomics | XXX | XXX | XXX | XXX | XXX | XXX |
| Genus | XXX | XXX | XXX | XXX | XXX | XXX |
| Adaptive Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
10x Genomics M&A Activity
10x Genomics acquired XXX companies to date.
Last acquisition by 10x Genomics was on XXXXXXXX, XXXXX. 10x Genomics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by 10x Genomics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free Trial10x Genomics Investment Activity
10x Genomics invested in XXX companies to date.
10x Genomics made its latest investment on XXXXXXXX, XXXXX. 10x Genomics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by 10x Genomics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout 10x Genomics
| When was 10x Genomics founded? | 10x Genomics was founded in 2012. |
| Where is 10x Genomics headquartered? | 10x Genomics is headquartered in United States. |
| How many employees does 10x Genomics have? | As of today, 10x Genomics has over 1K employees. |
| Who is the CEO of 10x Genomics? | 10x Genomics' CEO is Serge Saxonov. |
| Is 10x Genomics publicly listed? | Yes, 10x Genomics is a public company listed on Nasdaq. |
| What is the stock symbol of 10x Genomics? | 10x Genomics trades under TXG ticker. |
| When did 10x Genomics go public? | 10x Genomics went public in 2019. |
| Who are competitors of 10x Genomics? | 10x Genomics main competitors are Veracyte, Twist Bioscience, BGI Genomics, Genus. |
| What is the current market cap of 10x Genomics? | 10x Genomics' current market cap is $3B. |
| What is the current revenue of 10x Genomics? | 10x Genomics' last 12 months revenue is $636M. |
| What is the current revenue growth of 10x Genomics? | 10x Genomics revenue growth (NTM/LTM) is (2%). |
| What is the current EV/Revenue multiple of 10x Genomics? | Current revenue multiple of 10x Genomics is 3.8x. |
| Is 10x Genomics profitable? | No, 10x Genomics is not profitable. |
| What is the current EBITDA of 10x Genomics? | 10x Genomics has negative EBITDA and is not profitable. |
| What is 10x Genomics' EBITDA margin? | 10x Genomics' last 12 months EBITDA margin is (7%). |
| What is the current EV/EBITDA multiple of 10x Genomics? | Current EBITDA multiple of 10x Genomics is (55.1x). |
| What is the current FCF of 10x Genomics? | 10x Genomics' last 12 months FCF is ($8M). |
| What is 10x Genomics' FCF margin? | 10x Genomics' last 12 months FCF margin is (1%). |
| What is the current EV/FCF multiple of 10x Genomics? | Current FCF multiple of 10x Genomics is (289.6x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.